|
Oct 9
|
Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Oct 9
|
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
|
|
Oct 8
|
Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands
|
|
Sep 30
|
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
|
|
Sep 26
|
Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada
|
|
Jul 25
|
Organon & Co. (NYSE:OGN) is largely controlled by institutional shareholders who own 79% of the company
|
|
Jul 24
|
Organon (OGN) Upgraded to Strong Buy: What Does It Mean for the Stock?
|
|
Jul 9
|
Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
|
|
Jun 28
|
Do Options Traders Know Something About Organon (OGN) Stock We Don't?
|
|
Jun 3
|
Organon (OGN) Just Overtook the 20-Day Moving Average
|
|
May 8
|
Organon Announces Pricing of $1.0 Billion Senior Notes Offering
|
|
May 7
|
Organon Announces Proposed $1.0 Billion Senior Notes Offering
|
|
May 5
|
Organon (NYSE:OGN) Will Pay A Dividend Of $0.28
|
|
May 4
|
Organon First Quarter 2024 Earnings: EPS: US$0.79 (vs US$0.70 in 1Q 2023)
|
|
May 2
|
What Makes Organon (OGN) a New Buy Stock
|
|
May 2
|
Organon Reports Results for the First Quarter Ended March 31, 2024
|
|
Apr 25
|
Earnings Preview: Organon (OGN) Q1 Earnings Expected to Decline
|
|
Apr 8
|
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
|
|
Apr 8
|
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
|
|
Mar 8
|
On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health
|